Dynavax Technologies Corporation (DVAX) support and resistance · rev $277.2M
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page maps Dynavax Technologies Corporation (DVAX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported DVAX revenue for 2024-12-31 was $277.2M. Net income was $27.3M. Revenue was up 19.4% from 2023-12-31 to 2024-12-31. DVAX currently screens at market cap $1.82B.
DVAX currently screens at market cap $1.82B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new DVAX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the DVAX quote page for the session range and the stock page for the full model.
Not investment advice.